Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma. Recommendation based on IMROZ phase 3 study demonstrating Sarclis ...
HSBC, CGSI and UOBKH have kept their target price unchanged at $3.65, $3.70 and $3.58, respectively. Citi has kept its target price of $3.60, while RHB has a target price of $3.60 as well.
Millennial Potash Corp. is pleased to provide an update of the infrastructure build-up recently observed by MLP management at the Company's Banio Potash Project in Gabon. Progress has been made both ...
The end of summer time is the first harbinger of the approaching winter, the start of sales of the digital car vignette the ...
Gary Lineker will quit presenting Match of the Day at the end of the season after 26 years, the BBC appear to have confirmed ...
The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...
Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with ...
J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
Tunisia sanitation utility ONAS has issued a tender for a wastewater treatment plant for Skhira, Sfax. Deadline 21 Jan 2025 ...
The following is a summary of “Evolving treatment landscape of multiple myeloma in Portugal: A nation-wide retrospective ...
Five Pennsylvania counties are investigating possible fraudulent voter applications and mail-in ballot applications in the ...